17738-06-6

Usage

Uses

Used in Pharmaceutical Industry:
PYRIDIN-3-YL-CARBAMIC ACID PHENYL ESTER is utilized as an intermediate in the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, particularly those with potential antihypertensive and antitumor properties.
Used in Agrochemical Industry:
In the agrochemical sector, PYRIDIN-3-YL-CARBAMIC ACID PHENYL ESTER is employed as a pesticide due to its insecticidal and acaricidal activity. It helps protect crops from pests and contributes to maintaining agricultural productivity.
Safety Precautions:
Given its classification as a hazardous chemical, PYRIDIN-3-YL-CARBAMIC ACID PHENYL ESTER requires careful handling and storage. Appropriate safety measures should be taken to minimize risks associated with its use in both the pharmaceutical and agrochemical industries.

Upstream product

• 462-08-8 pyridin-3-ylamine 
• 1885-14-9 phenyl chloroformate 
• 626-60-8 3-Chloropyridine 
• 917-61-3 sodium isocyanate 
• 108-95-2 phenol 

Downstream Products

• 282114-82-3 (2S)-N-(2-tetrahydropyranyloxy)-2-[5-(3-(3-pyridylaminocarbonylamino)phenyl)-2-thienyl]-3,4,5,6-tetrahydro-2H-thiopyran-2-acetamide 1,1-dioxide 
• 1020315-07-4 N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide 
• 1020316-82-8 4-(3-(5-cyanopyridin-2-yloxy)benzylidene)-N-(pyridin-3-yl)piperidine-1-carboxamide 
• 1020317-00-3 4-{3-[(5-bromopyridin-2-yl)oxy]benzylidene}-N-pyridin-3-ylpiperidine-1-carboxamide 
• 1020317-18-3 4-(3-(5-bromopyrimidin-2-yloxy)benzylidene)-N-(pyridin-3-yl)piperidine-1-carboxamide 
• 1020317-30-9 4-(3-(5-cyclopropylpyridin-2-yloxy)benzylidene)-N-(pyridin-3-yl)piperidine-1-carboxamide 
• 1020317-43-4 4-(3-(6-methylpyridin-2-yloxy)benzylidene)-N-(pyridin-3-yl)piperidine-1-carboxamide 
• 1020317-57-0 4-(3-(3-methylpyridin-2-yloxy)benzylidene)-N-(pyridin-3-yl)piperidine-1-carboxamide 
• 1020317-71-8 4-(3-(5-methylpyridin-2-yloxy)benzylidene)-N-(pyridin-3-yl)piperidine-1-carboxamide 
• 1020317-92-3 4-(3-(5-ethoxypyridin-2-yloxy)benzylidene)-N-(pyridin-3-yl)piperidine-1-carboxamide 
• 1020318-06-2 4-(3-(5-(2,2,2-trifluoroethoxy)pyridin-2-yloxy)benzylidene)-N-(pyridin-3-yl)piperidine-1-carboxamide 
• 1020318-21-1 4-(3-(5-isopropoxypyridin-2-yloxy)benzylidene)-N-(pyridin-3-yl)piperidine-1-carboxamide 
• 1020318-37-9 4-(3-(4-(trifluoromethyl)phenoxy)benzylidene)-N-(pyridin-3-yl)piperidine-1-carboxamide 
• 1020318-74-4 4-(3-ethoxy-5-(5-(trifluoromethyl)pyridin-2-yloxy)benzylidene)-N-(pyridin-3-yl)piperidine-1-carboxamide 

Relevant academic research and scientific papers

Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core

Janus kinases (JAKs) are non-receptor tyrosine kinases that are essential components of the JAK-STAT signaling pathway. Associated aberrant signaling is responsible for many forms of cancer and disorders of the immune system. The present focus is on the d

Synthesis, cytotoxicity, and in vivo antitumor activity study of parthenolide semicarbazones and thiosemicarbazones

Parthenolide is an important sesquiterpene lactone with potent anticancer activities. In order to further improve its biological activity, a series of parthenolide semicarbazone or thiosemicarbazone derivatives was synthesized and evaluated for their anti

Synthesis and Structure–Activity Relationship Studies of Benzo[b][1,4]oxazin-3(4H)-one Analogues as Inhibitors of Mycobacterial Thymidylate Synthase X

Since the discovery of a flavin-dependent thymidylate synthase (ThyX or FDTS) that is absent in humans but crucial for DNA biosynthesis in a diverse group of pathogens, the enzyme has been pursued for the development of new antibacterial agents against Mycobacterium tuberculosis, the causative agent of the widespread infectious disease tuberculosis (TB). In response to a growing need for more effective anti-TB drugs, we have built upon our previous screening efforts and report herein an optimization campaign of a novel series of inhibitors with a unique inhibition profile. The inhibitors display competitive inhibition toward the methylene tetrahydrofolate cofactor of ThyX, enabling us to generate a model of the compounds bound to their target, thus offering insight into their structure–activity relationships.

DIAZABICYCLOOCTANE DERIVATIVES COMPRISING A QUATERNERY AMMONIUM GROUP FOR USE AS ANTIBACTERIAL AGENTS

Compounds of Formula (I), pharmaceutical compositions comprising these compounds and their use in treating bacterial infection is disclosed.

Synthesis and evaluation of novel dimethylpyridazine derivatives as hedgehog signaling pathway inhibitors

We report herein the design and synthesis of a series of structural modified dimethylpyridazine compounds as novel hedgehog signaling pathway inhibitors. The bicyclic phthalazine core and 4-methylamino-piperidine moiety of Taladegib were replaced with dim

The SAR of brain penetration for a series of heteroaryl urea FAAH inhibitors

The SAR of brain penetration for a series of heteroaryl piperazinyl- and piperadinyl-urea fatty acid amide hydrolase (FAAH) inhibitors is described. Brain/plasma (B/P) ratios ranging from >4:1 to as low as 0.02:1 were obtained through relatively simple st

SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS

The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

SUBSTITUTED OXAZOLE- AND THIAZOLE-BASED CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS II

The invention relates to oxazole and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS

The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS

The present invention provides substituted 4,5-dihydroisoxazole derivatives of formula (I), which may be therapeutically useful, more particularly NAMPT inhibitors and in which R1 R2, Y, X, "Het" and "p" have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPT) in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted 4,5-dihydroisoxazole derivatives of formula (I) or a pharmaceutically acceptable salts or stereoisomers or N-oxide thereof.